Predictors and Outcomes of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Aggressive B-Cell Non-Hodgkin Lymphoma.
Predictors and Outcomes of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Aggressive B-Cell Non-Hodgkin Lymphoma. Transplant Cell Ther. 2026 Oct 21.
PMID: 42906792
Favorable Survival for Older Adults Treated With Axi-cel and Tisa-cel CD19 CAR-T Therapy for Relapsed/Refractory DLBCL: A U.S. Multicenter Comparative Analysis.
Favorable Survival for Older Adults Treated With Axi-cel and Tisa-cel CD19 CAR-T Therapy for Relapsed/Refractory DLBCL: A U.S. Multicenter Comparative Analysis. Transplant Cell Ther. 2026 Oct 19.
PMID: 42896626
Real-world outcomes of nivolumab-AVD and brentuximab vedotin-AVD in paediatric and adult advanced-stage Hodgkin lymphoma.
Real-world outcomes of nivolumab-AVD and brentuximab vedotin-AVD in paediatric and adult advanced-stage Hodgkin lymphoma. Br J Haematol. 2026 Sep 27.
PMID: 42802099
Late cytopenia after CD19 chimeric antigen receptor T-cell therapy in large B-cell lymphoma: a Cell Therapy Consortium analysis.
Late cytopenia after CD19 chimeric antigen receptor T-cell therapy in large B-cell lymphoma: a Cell Therapy Consortium analysis. Blood Adv. 2026 09 22; 10(18):6188-6197.
PMID: 42341321
B-Cell Lymphomas, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.
B-Cell Lymphomas, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2026 Sep; 24(9).
PMID: 42753811
Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy.
Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy. Cancer Immunol Res. 2026 Aug 04; 14(8):1292-1306.
PMID: 42112708
Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004.
Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004. Blood. 2026 Jul 28.
PMID: 42520199
Longitudinal patient-reported outcomes and quality-of-life trajectories over 2 years in CAR-T therapy recipients.
Longitudinal patient-reported outcomes and quality-of-life trajectories over 2 years in CAR-T therapy recipients. Blood Neoplasia. 2026 Nov; 3(4):100278.
PMID: 42718878
Comparison of Fludarabine Versus Bendamustine as a Lymphodepleting Chemotherapy Prior to CAR-T for Large Cell Lymphoma.
Comparison of Fludarabine Versus Bendamustine as a Lymphodepleting Chemotherapy Prior to CAR-T for Large Cell Lymphoma. Transplant Cell Ther. 2026 Jun 24.
PMID: 42341926
Outcomes and Safety of CAR-T Cell Therapy in B-NHL Patients With Reduced Left Ventricular Ejection Fraction.
Outcomes and Safety of CAR-T Cell Therapy in B-NHL Patients With Reduced Left Ventricular Ejection Fraction. Transplant Cell Ther. 2026 Oct; 32(10):1240.e1-1240.e5.
PMID: 42217793